Sea Otter Advisors’s Estrella Immunopharma Warrant ESLAW Stock Holding History

Sea Otter Advisors’s Portfolio ESLAW Stock Details ESLAW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-40,000	Closed	-$2.22K	–	264
2023 Q2	$2.22K	Hold	40,000	–	–	﹤0.01%	227
2023 Q1	$4.09K	Buy	+40,000	New	+$2.61K	﹤0.01%	219

Other funds holding ESLAW

Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return

ATW SPAC Management New York $79.2M AUM 10.67% 1-Year Est. Return

EHP Funds Inc Toronto, Canada $43.6M AUM 69.08% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

SkyView Investment Advisors Shrewsbury, New Jersey $743M AUM 17.91% 1-Year Est. Return

Yakira Capital Management Westport, Connecticut $342M AUM 26.97% 1-Year Est. Return

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Clear Street New York $24.6B AUM 56.26% 1-Year Est. Return

Susquehanna International Group

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Magnus Financial Group New York $1.41B AUM 23.4% 1-Year Est. Return

Sea Otter Advisors's ESLAW Position: Q3 2023 in Review

Sea Otter Advisors sold out of Estrella Immunopharma Warrant (ESLAW) in Q3 2023, closing a stake of 40,000 shares — an estimated $2.22K sold.

Sea Otter Advisors first reported a position in ESLAW in Q1 2023 and held it in 2 quarters. The position peaked at $4.09K in Q1 2023. 11 funds tracked by Wall St. Rank hold ESLAW as of Q3 2023.

Sea Otter Advisors reported no remaining Estrella Immunopharma Warrant position as of Q3 2023 after selling out during the quarter.
Sea Otter Advisors sold 40,000 Estrella Immunopharma Warrant shares in Q3 2023, an estimated $2.22K.
Sea Otter Advisors first reported a position in Estrella Immunopharma Warrant in Q1 2023 and held it in 2 quarters.
Sea Otter Advisors's Estrella Immunopharma Warrant position peaked at $4.09K in Q1 2023.
11 funds tracked by Wall St. Rank held Estrella Immunopharma Warrant as of Q3 2023.

Based on Sea Otter Advisors's 13F filing for Q3 2023, filed 14 Nov 2023.